Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
3.09
Industry P/E
--
Debt to Equity
-0.06
ROE
-26.34 %
ROCE
-1199.85 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
A$-106.10 Mln
EBITDA
A$-122.94 Mln
Net Profit
A$-119.65 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
| -91.77 | -23.38 | -91.44 | -96.26 | -87.49 | -65.17 | -52.72 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
| -59.47 | -28.44 | -92.76 | -2.55 | 99.08 | 78.60 | -23.47 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the... phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Read more
CEO, MD & Director
Dr. John Edwin Friend II, M.D.
CEO, MD & Director
Dr. John Edwin Friend II, M.D.
Headquarters
Sydney, NSW
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kazia Therapeutics Limited - ADR stood at $ 22 Mln as on 30-Jun-24
The share price of Kazia Therapeutics Limited - ADR is $3.64 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Kazia Therapeutics Limited - ADR has given a return of -87.49% in the last 3 years.
Kazia Therapeutics Limited - ADR has a market capitalisation of $ 4 Mln as on 25-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Kazia Therapeutics Limited - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kazia Therapeutics Limited - ADR and enter the required number of quantities and click on buy to purchase the shares of Kazia Therapeutics Limited - ADR.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
The CEO & director of Dr. John Edwin Friend II, M.D.. is Kazia Therapeutics Limited - ADR, and CFO & Sr. VP is Dr. John Edwin Friend II, M.D..
There is no promoter pledging in Kazia Therapeutics Limited - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Kazia Therapeutics Limited - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-2633.62
|
|
Operating margin(%)
|
-1240.68
|
|
Net Margin(%)
|
-1160.23
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kazia Therapeutics Limited - ADR was $-7 Mln.
$0.22
(
